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SI/CTR Abstract
Survivorship, Complications, and Outcomes Following Distal Femoral Replacement
Using Megaprosthesis
Keenan Sobol BS, John Strony BS, Timothy Tan MD, Scot Brown MD*

Introduction
Distal femoral bone loss is often managed with a combination of modular prostheses,
structural and non-structural allografts, and metal augmentation. However, when bone
loss of the distal femur is severe, the viability of these methods can be limited. In the
setting of severe bone loss, endoprosthetic reconstruction (EPR) with a megaprosthesis
has become increasingly popular for both malignant and non-neoplastic indications. The
primary aim of this study was to determine the short-term prosthesis survivorship, as well
as complications, for patients who presented with non-neoplastic disease indications for
megaprosthesis distal femoral replacement (DFR) at a single institution. The secondary
aim was to identify factors that influenced the outcome of DFR.
Methods
A retrospective review was performed to identify patients who underwent megaprosthetic
DFR surgery for a non-neoplastic indication, including native and preiprosthetic
fractures, septic and aseptic nonunion, periprosthetic joint infection (PJI), and aseptic
loosening or mechanical failure of a previous prosthesis. Information regarding
complications, reoperations, demographics and comorbidities were recorded, excluding
patients with less than 24 months follow-up. Reoperation for implant failure was used as
the final endpoint for survivorship.

Results
Seventy-five patients were identified. DFR survivorship was 86% at one year and 76% at
five years. Patients who sustained a native fracture or had non-union demonstrated the
highest survival rate at one and five years, (91%, 82% respectively) followed by patients
with aseptic loosening or mechanical failure of previous implants, and then patients with
PJI. A total of 36 (48 %) patients experienced at least one post-operative complication
and 27 patients (36%) required at least one reoperation. Fracture, aseptic loosening, and
PJI were complications more likely to require reoperation for prosthesis failure.
Furthermore, patient demographics and comorbidities were not significant for predicting
failure.
Discussion
DFR is a viable surgical option for significant distal femoral bone loss with good shortterm survivorship. There is a high overall complication rate, however the complication
profile, as well as survivorship may vary based on the initial indication for DFR.

